Šalis: Kanada
kalba: anglų
Šaltinis: Health Canada
POSACONAZOLE
APOTEX INC
J02AC04
POSACONAZOLE
100MG
TABLET (DELAYED-RELEASE)
POSACONAZOLE 100MG
ORAL
100
Prescription
AZOLES
Active ingredient group (AIG) number: 0152201002; AHFS:
APPROVED
2021-01-29
Page 1 of 41 PRODUCT MONOGRAPH PR APO-POSACONAZOLE Posaconazole Delayed-Release Tablets 100 mg posaconazole Antifungal Agent APOTEX INC. 150 SIGNET DRIVE, TORONTO, ONTARIO M9L 1T9 DATE OF REVISION: January 28, 2021 Submission Control No: 232111 Page 1 of 41 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ............................................................................... 2 SUMMARY PRODUCT INFORMATION ............................................................................................... 2 INDICATIONS AND CLINICAL USE ..................................................................................................... 2 CONTRAINDICATIONS .......................................................................................................................... 3 WARNINGS AND PRECAUTIONS ......................................................................................................... 3 ADVERSE REACTIONS ........................................................................................................................... 6 DRUG INTERACTIONS ......................................................................................................................... 13 DOSAGE AND ADMINISTRATION ..................................................................................................... 19 OVERDOSAGE ....................................................................................................................................... 21 ACTION AND CLINICAL PHARMACOLOGY ................................................................................... 21 STORAGE AND STABILITY ................................................................................................................. 25 SPECIAL HANDLING INSTRUCTIONS .............................................................................................. 25 DOSAGE FORMS, COMPOSITION AND PACKAGING .................................................................... 25 PART II: SCIENTIFIC INFORMATION ................ Perskaitykite visą dokumentą